

# Francois X Claret

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9397746/publications.pdf>

Version: 2024-02-01

83  
papers

8,682  
citations

57719

44  
h-index

66879

78  
g-index

85  
all docs

85  
docs citations

85  
times ranked

9081  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. <i>Cell</i> , 1995, 81, 1147-1157.	13.5	1,515
2	Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. <i>Science</i> , 1995, 268, 286-290.	6.0	770
3	Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. <i>Nature</i> , 1994, 370, 226-229.	13.7	748
4	Withdrawal of Survival Factors Results in Activation of the JNK Pathway in Neuronal Cells Leading to Fas Ligand Induction and Cell Death. <i>Molecular and Cellular Biology</i> , 1999, 19, 751-763.	1.1	442
5	A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. <i>Nature</i> , 1996, 383, 453-457.	13.7	441
6	Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 62.	1.3	427
7	Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 19245-19256.	1.6	319
8	Lasting N-Terminal Phosphorylation of c-Jun and Activation of c-Jun N-Terminal Kinases after Neuronal Injury. <i>Journal of Neuroscience</i> , 1998, 18, 5124-5135.	1.7	312
9	A nucleosome-dependent static loop potentiates estrogen-regulated transcription from the <i>Xenopus vitellogenin B1</i> promoter in vitro. <i>EMBO Journal</i> , 1993, 12, 423-433.	3.5	204
10	Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. <i>Cancer Research</i> , 2006, 66, 6589-6597.	0.4	187
11	Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 9653-9661.	1.6	172
12	AP-1 Transcription Factors as Regulators of Immune Responses in Cancer. <i>Cancers</i> , 2019, 11, 1037.	1.7	166
13	The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition. <i>Journal of Biological Chemistry</i> , 2003, 278, 23441-23450.	1.6	132
14	JAB1/CSN5: a new player in cell cycle control and cancer. <i>Cell Division</i> , 2010, 5, 26.	1.1	132
15	Mutual regulation of microRNAs and DNA methylation in human cancers. <i>Epigenetics</i> , 2017, 12, 187-197.	1.3	116
16	Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1273-1278.	3.3	115
17	Stat3 Inhibitor Stattic Exhibits Potent Antitumor Activity and Induces Chemo- and Radio-Sensitivity in Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2013, 8, e54565.	1.1	108
18	N-(4-Hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. <i>Oncogene</i> , 2006, 25, 2785-2794.	2.6	93

#	ARTICLE	IF	CITATIONS
19	2-Acetylaminofluorene Up-regulates Rat mdr1b Expression through Generating Reactive Oxygen Species That Activate NF- $\kappa$ B Pathway. <i>Journal of Biological Chemistry</i> , 2001, 276, 413-420.	1.6	92
20	All- <i>trans</i> -Retinoic Acid Inhibits Jun N-Terminal Kinase by Increasing Dual-Specificity Phosphatase Activity. <i>Molecular and Cellular Biology</i> , 1999, 19, 1973-1980.	1.1	91
21	Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. <i>Blood</i> , 2005, 105, 827-829.	0.6	88
22	Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. <i>Journal of Leukocyte Biology</i> , 2013, 94, 423-429.	1.5	77
23	Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5. <i>Oncogene</i> , 2016, 35, 6096-6108.	2.6	74
24	A nuclear factor I-like activity and a liver-specific repressor govern estrogen-regulated in vitro transcription from the <i>Xenopus laevis</i> vitellogenin B1 promoter.. <i>Molecular and Cellular Biology</i> , 1989, 9, 5548-5562.	1.1	73
25	NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. <i>Blood</i> , 2007, 110, 1621-1630.	0.6	72
26	JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. <i>Modern Pathology</i> , 2005, 18, 1365-1370.	2.9	69
27	Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. <i>Oncogene</i> , 2013, 32, 2756-2766.	2.6	68
28	Jab1/CSN5 Negatively Regulates p27 and Plays a Role in the Pathogenesis of Nasopharyngeal Carcinoma. <i>Cancer Research</i> , 2012, 72, 1890-1900.	0.4	65
29	Cisplatin Resistance in an Ovarian Carcinoma Is Associated With a Defect in Programmed Cell Death Control Through XIAP Regulation. <i>Oncology Research</i> , 2003, 13, 399-404.	0.6	65
30	Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. <i>Cancer Immunology Research</i> , 2020, 8, 952-965.	1.6	63
31	Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. <i>Oncogene</i> , 2010, 29, 6125-6137.	2.6	61
32	RBM24 suppresses cancer progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma. <i>Cell Death and Disease</i> , 2016, 7, e2352-e2352.	2.7	58
33	Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. <i>Cancer Research</i> , 2006, 66, 8581-8589.	0.4	57
34	Involvement of microRNA-24 and DNA Methylation in Resistance of Nasopharyngeal Carcinoma to Ionizing Radiation. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3163-3174.	1.9	56
35	c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 184-194.	3.2	55
36	Phosphatases: The New Brakes for Cancer Development?. <i>Enzyme Research</i> , 2012, 2012, 1-11.	1.8	54

#	ARTICLE	IF	CITATIONS
37	Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy. <i>Cancer Letters</i> , 2017, 411, 82-89.	3.2	54
38	Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). <i>Leukemia</i> , 2011, 25, 856-867.	3.3	53
39	Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 256-262.	1.5	53
40	Jab1/Csn5 "Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. <i>Clinical Cancer Research</i> , 2017, 23, 4450-4461.	3.2	53
41	Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention. <i>Blood Reviews</i> , 2013, 27, 261-267.	2.8	51
42	Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells. <i>Breast Cancer Research</i> , 2011, 13, R65.	2.2	48
43	Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression. <i>Oncogene</i> , 2017, 36, 1069-1079.	2.6	48
44	Targeting Jab1/CSN5 in nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2012, 326, 155-160.	3.2	47
45	MicroRNAs as Therapeutic Targets in Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 756.	1.3	41
46	Down "regulation of the cyclin "dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis. <i>Hepatology</i> , 2016, 63, 898-913.	3.6	40
47	Jab1/COP55 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 135.	1.6	39
48	Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. <i>FEBS Letters</i> , 2005, 579, 3932-3940.	1.3	36
49	Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. <i>Journal of Endocrinology</i> , 2003, 176, 103-110.	1.2	35
50	Estrogen receptor level determines sex-specific in vitro transcription from the Xenopus vitellogenin promoter.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 7878-7882.	3.3	34
51	Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival. <i>PLoS ONE</i> , 2020, 15, e0231003.	1.1	33
52	Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2013, 13, 323.	1.1	32
53	Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 353-365.	3.3	30
54	The Role of p27 Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1403-1422.	3.0	26

#	ARTICLE	IF	CITATIONS
55	The oncogenic <sc>JUNB</sc>/<sc>CD</sc>30 axis contributes to cell cycle deregulation in <sc>ALK</sc>+ anaplastic large cell lymphoma. British Journal of Haematology, 2014, 167, 514-523.	1.2	25
56	Activator Protein-1 Has an Essential Role in Pancreatic Cancer Cells and Is Regulated by a Novel Akt-Mediated Mechanism. Molecular Cancer Research, 2009, 7, 745-754.	1.5	23
57	MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Letters, 2019, 465, 12-23.	3.2	21
58	Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51. Cellular Signalling, 2019, 53, 39-48.	1.7	21
59	A shift in the Ligand Responsiveness of Thyroid Hormone Receptor $\beta$ Induced by Heterodimerization with Retinoid X Receptor $\beta$ . Molecular and Cellular Biology, 1996, 16, 219-227.	1.1	18
60	Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism. Leukemia, 2015, 29, 2162-2172.	3.3	18
61	Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma. Oncology Reports, 2015, 33, 1418-1426.	1.2	18
62	Clinical implications of hepatitis B viral infection in Epsteinâ€Barr virus-associated nasopharyngeal carcinoma. Journal of Clinical Virology, 2015, 64, 64-71.	1.6	18
63	Role of cancerâ€associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in nonâ€small cell lung cancer (Review). Oncology Letters, 2021, 21, 413.	0.8	17
64	The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells. Neoplasma, 2019, 66, 481-486.	0.7	16
65	Regioselective Electrophilic Additions of Bicyclo[2.2.n]alk-2-enes Controlled by Remote Epoxide Functions. Helvetica Chimica Acta, 1987, 70, 1886-1896.	1.0	15
66	Expression of serine 194â€phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell nonâ€Hodgkin lymphomas. Human Pathology, 2011, 42, 1117-1124.	1.1	12
67	Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. International Journal of Oncology, 2007, , .	1.4	11
68	Immuno-electron microscopic identification of human estrogen receptor-DNA complexes at the estrogen-responsive element and in the first intron of a Xenopus vitellogenin gene. Journal of Molecular Biology, 1988, 204, 217-220.	2.0	10
69	hsaâ€miRâ€24 suppresses metastasis in nasopharyngeal carcinoma by regulating the câ€Myc/epithelialâ€mesenchymal transition axis. Oncology Reports, 2018, 40, 2536-2546.	1.2	9
70	Synthesis of (1RS,2RS,5SR)-3,4,6,7-tetramethylidene-8-oxobicyclo[3.2.1]oct-2-yl acetate and the chemo- and stereoselective coordination of its butadiene functions with rhodium and iron moieties. Organometallics, 1990, 9, 2785-2792.	1.1	8
71	Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 374.	3.5	8
72	Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epsteinâ€Barr virus DNA load. Proteomics - Clinical Applications, 2017, 11, 1600090.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Identification of a seven-long non-coding RNA signature associated with Jab1/CSN5 in predicting hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 178.	2.0	6
74	&lt;p&gt;YAP1 Promotes Tumor Invasion and Metastasis in Nasopharyngeal Carcinoma with Hepatitis B Virus Infection&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5629-5642.	1.0	4
75	Jab1/Csn5 Signaling in Breast Cancer. , 2017, , .		2
76	TheDiels-Alder Chemoselectivity of 3,4,6,7-Tetramethylidenebicyclo[3.2.1]octane-2-exo, 8-syn-diyl Derivatives. <i>Helvetica Chimica Acta</i> , 1992, 75, 1085-1094.	1.0	1
77	Abstract LB-B03: miR-24 acts as a tumor suppressor and radiosensitizer by targeting Jab1/CSN5 functions. <i>Molecular Cancer Therapeutics</i> , 2015, 14, LB-B03-LB-B03.	1.9	1
78	Abstract 4286: Essential Roles of Jab1 in Cell Survival, Spontaneous DNA Damage, and DNA Repair. , 2011, , .		0
79	Abstract 1855: Jab1/CSN5 a negative regulator of p27 plays a role in the pathogenesis and cisplatin sensitivity of nasopharyngeal carcinoma. , 2012, , .		0
80	Abstract 1912: Jab1/Csn5 as a novel driver for therapeutic resistance in HER2-positive breast cancer. , 2012, , .		0
81	Abstract B231: Jab1/Csn5 a new player driving the resistance to Her2-targeted therapies for breast cancer.. , 2013, , .		0
82	Abstract 1825: Jab1/Csn5 a new target in the resistant mechanism to HER2-targeted therapies for breast cancer. , 2014, , .		0
83	NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation. <i>Blood</i> , 2019, 134, 2796-2796.	0.6	0